{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009939","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.174207+00:00","generated_at":"2026-05-21T14:19:46.729001+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Daré Bioscience Q1 2025: Cash $10.3M, R&D down 31%, expects first revenue in Q4 2025","bullets":["Cash and equivalents $10.3M at March 31, 2025; working capital deficit of $9.4M.","R&D expenses fell 31% YoY to $2.3M; G&A expenses decreased to $2.3M from $2.7M.","Targeting first revenue in Q4 2025 via Sildenafil Cream as 503B compounded drug; DARE-HRT1 in 2026.","Ovaprene Phase 3 contraceptive efficacy study ongoing; interim DSMB review scheduled for July 2025.","Strategy shift: dual path of 503B compounding and FDA approval; aiming for four on-market products by 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009939","json":"https://secwatch.observer/filing/0001641172-25-009939.json","markdown":"https://secwatch.observer/filing/0001641172-25-009939.md","text":"https://secwatch.observer/filing/0001641172-25-009939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000164117225009939/0001641172-25-009939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000164117225009939/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T14:19:46.729001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}